Login to Your Account



Clinic Roundup


Thursday, June 30, 2011
QRxPharma Ltd., of Sydney, Australia, said additional data from the Phase III trial of MoxDuo IR (morphine/oxycodone) showed the drug reduced the risk of severe oxygen desaturation compared to morphine or oxycodone alone. A new drug application filing is slated for later this year.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription